Drug Trial Radar · NCT07929805
ACT201 Injection in Participants With Chronic Hepatitis B (CHB) on Nucleos(t)Ide Analog Therapy - Phase Ib
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Nov 20, 2026
Primary completion
Feb 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Xiamen Amoytop Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- The First Affiliated Hospital of Xiamen University
- First posted
- Nov 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, open-label, parallel-controlled Phase Ib clinical trial. It aims to evaluate the safety and preliminary efficacy of ACT201 Injection combined with standard therapy (PegIFNα, NA) in participants with chronic hepatitis B who are receiving NA treatment. A total of 40 participants with chronic hepatitis B will be enrolled. Eligible participants should have stable NA treatment, HBV DNA \< 100 IU/mL, negative HBeAg, and HBsAg ≤ 100 IU/mL. They will be randomized into four treatment groups at a 1:1:1:1 ratio.
Conditions
- Chronic Hepaititis B
Interventions
ACT201 InjectionDrug
Subcutaneous injection per assigned dose group; treatment duration shall follow the study protocol.
ACT201 InjectionDrug
Subcutaneous injection per assigned dose group; treatment duration shall follow the study protocol.
ACT201 InjectionDrug
Subcutaneous injection per assigned dose group; treatment duration shall follow the study protocol.
ACT201 InjectionDrug
Subcutaneous injection per assigned dose group; treatment duration shall follow the study protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety: number of participants with adverse event (AE), serious adverse events (SAE) and clinically significant examination results. Assessments include vital signs, physical examinations, laboratory tests, and 12-lead electrocardiograms (ECGs).Time frame: throughout the full study period,an average of 38 weeks
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Beijing Ditan Hospital, Capital Medical University
Beijing, China
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
The Second Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
The First Affiliated Hospital of Xiamen University
Xiamen, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.